Will NVIDIA Return to Its 52-Week High?
NVIDIA (NASDAQ:NVDA) has been among the best-performing investments of the…
Sell
31
OCUL Quote, Financials, Valuation and Earnings
Last price:
$7.10
Seasonality move
:
-6.31%
Day range:
$6.21 - $7.20
52-week range:
$4.06 - $11.78
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
17.66x
P/B ratio:
3.59x
Volume:
1.6M
Avg. volume:
1.9M
1-year change:
-14.13%
Market cap:
$1.1B
Revenue:
$63.7M
EPS (TTM):
-$1.26
Analysts' Opinion
-
Consensus RatingOcular Therapeutix has received a consensus rating of Buy. The company's average rating is a Buy based on 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $17.50, Ocular Therapeutix has an estimated upside of 146.13% from its current price of $7.11.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $14.00 representing 100% downside risk from its current price of $7.11.
Fair Value
-
According to the consensus of 6 analysts, Ocular Therapeutix has 146.13% upside to fair value with a price target of $17.50 per share.
OCUL vs. S&P 500
-
Over the past 5 trading days, Ocular Therapeutix has overperformed the S&P 500 by 5.85% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Ocular Therapeutix does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ocular Therapeutix has grown year-over-year revenues for 9 quarters straight. In the most recent quarter Ocular Therapeutix reported revenues of $17.1M.
Earnings Growth
-
Ocular Therapeutix has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Ocular Therapeutix reported earnings per share of -$0.29.
Enterprise value:
807.1M
EV / Invested capital:
--
Price / LTM sales:
17.66x
EV / EBIT:
--
EV / Revenue:
12.67x
PEG ratio (5yr expected):
-7.05x
EV / Free cash flow:
-5.94x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$58.1M
Return On Assets:
-42.88%
Net Income Margin (TTM):
-303.67%
Return On Equity:
-62.66%
Return On Invested Capital:
-51.22%
Operating Margin:
-296.08%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $51.5M | $58.4M | $63.7M | $14.8M | $17.1M | |
| Gross Profit | $47M | $53.2M | $58.1M | $13.4M | $15.9M | |
| Operating Income | -$78.7M | -$82.4M | -$171.8M | -$20.1M | -$50.6M | |
| EBITDA | -$61.9M | -$66.4M | -$176.1M | -$24.1M | -$44.3M | |
| Diluted EPS | -$1.02 | -$1.25 | -$1.26 | -$0.35 | -$0.29 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $246.2M | $191.3M | $129.6M | $232.2M | $441M | |
| Total Assets | $261.9M | $204.9M | $149.3M | $252.1M | $457.9M | |
| Current Liabilities | $26.7M | $26.3M | $31.4M | $34.9M | $41.4M | |
| Total Liabilities | $185.8M | $116.9M | $113.9M | $160.9M | $142.6M | |
| Total Equity | $76.1M | $88M | $35.4M | $91.1M | $315.3M | |
| Total Debt | $49.5M | $51.4M | $54M | $74.9M | $68.5M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$59.6M | -$70.2M | -$134.7M | -$22.5M | -$39.4M | |
| Cash From Investing | -$3.7M | -$6.1M | -$1.3M | -$459K | -$202K | |
| Cash From Financing | $1.5M | $169.8M | $332.1M | $108.2M | $4.5M | |
| Free Cash Flow | -$63.3M | -$76.3M | -$136M | -$22.9M | -$39.6M | |
OCUL
Sector
Market Cap
$1.1B
$33.9M
Price % of 52-Week High
60.38%
41.2%
Dividend Yield
0%
0%
Shareholder Yield
-23.4%
-0.91%
1-Year Price Total Return
-14.13%
-46.15%
Beta (5-Year)
1.491
0.743
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$6.67
200-day SMA
Sell
Level
$8.44
Bollinger Bands (100)
Sell
Level
7.1 - 9.02
Chaikin Money Flow
Sell
Level
-62.4M
20-day SMA
Sell
Level
$7.17
Relative Strength Index (RSI14)
Sell
Level
49.94
ADX Line
Sell
Level
19.63
Williams %R
Neutral
Level
-41.5179
50-day SMA
Sell
Level
$7.32
MACD (12, 26)
Sell
Level
-0.25
25-day Aroon Oscillator
Sell
Level
-80
On Balance Volume
Neutral
Level
35.6M
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (2.8343)
Sell
CA Score
(Annual)
Level (-2.3473)
Buy
Beneish M-Score
(Annual)
Level (-2.9903)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (2.0283)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Stock Forecast FAQ
In the current month, OCUL has received 6 Buy ratings 0 Hold ratings, and 0 Sell ratings. The OCUL average analyst price target in the past 3 months is $17.50.
-
Where Will Ocular Therapeutix Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ocular Therapeutix share price will rise to $17.50 per share over the next 12 months.
-
What Do Analysts Say About Ocular Therapeutix?
Analysts are divided on their view about Ocular Therapeutix share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ocular Therapeutix is a Sell and believe this share price will drop from its current level to $14.00.
-
What Is Ocular Therapeutix's Price Target?
The price target for Ocular Therapeutix over the next 1-year time period is forecast to be $17.50 according to 6 Wall Street analysts, 6 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is OCUL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ocular Therapeutix is a Buy. 6 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of OCUL?
You can purchase shares of Ocular Therapeutix via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ocular Therapeutix shares.
-
What Is The Ocular Therapeutix Share Price Today?
Ocular Therapeutix was last trading at $7.10 per share. This represents the most recent stock quote for Ocular Therapeutix. Yesterday, Ocular Therapeutix closed at $7.11 per share.
-
How To Buy Ocular Therapeutix Stock Online?
In order to purchase Ocular Therapeutix stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will JP Morgan’s AI Advisor Be a Winner?
JPMorgan Chase is rolling out “JPM WealthAI for high-net-worth clients.…
Is Revolve Group Stock a Buy, Sell or Hold?
Recently, Revolve Group (NYSE:RVLV) management delivered some fairly positive business…
Stock Ideas
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
50
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
52
RGC alert for Apr 12
Regencell Bioscience Holdings [RGC] is up 29.14% over the past day.
Buy
52
SLP alert for Apr 12
Simulations Plus [SLP] is up 26.73% over the past day.
Buy
89
GDXU alert for Apr 12
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 15.9% over the past day.
